Report on the 56th ASH Annual Meeting, San Francisco, 4-9 December 2014

Research output: Contribution to journalArticlepeer-review


The 56th annual ASH (American Society of Haematology) meeting was held in San Francisco (CA). More than 3,000 abstracts were selected for presentation due to the huge amount of information from basic science to clinical experience. The future direction in haematoncology is targeted therapies for most diseases; for instance, anti-PD-1 and CAR-T cells in lymphoproliferative disorders and novel immunomodulatory agents active in the contest of bone marrow milieu in multiple myeloma. On the other hand, in aggressive haematological diseases (AML, ALL), clinical studies demonstrated the feasibility of a more intensive chemotherapy approach in older patients.

Original languageEnglish
Article number514
Publication statusPublished - Feb 26 2015


  • Chimeric antigen receptors
  • Intensive chemotherapy
  • PD-1 inhibitors
  • Target therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Report on the 56th ASH Annual Meeting, San Francisco, 4-9 December 2014'. Together they form a unique fingerprint.

Cite this